Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Jeffrey Wong, MD, discusses the evolving field of combination therapy with radiopharmaceuticals in prostate cancer. In an interview with Targeted Oncology TM, Jeffrey Wong, MD, radiation oncologist ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Artificial intelligence can help urologists and oncologists make treatment recommendations that are objective and evidence-based.

Uropathologists, for the first time, acknowledge issues with indolent Grade Group 1 tumors, which are leading to ...

Cancer patients in British Columbia will no longer be referred to clinics in Bellingham, Wash., for care, Health Minister Josie Osborne announced Monday. Osborne says the ministry's decision was not a ...

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunotherapy, CAR-T cell therapy, and biomarker-based ...

The 34-year-old continued to say that she believes chemotherapy is "off the table ... cancer journeys... The All My Children alum announced in January 2025 that he had been diagnosed with ...

Moderately hypofractionated and conventionally fractionated radiotherapy demonstrate similar efficacy, but one hypofractionated approach has a better toxicity profile.

If detected early, prostate cancer has a high survival rate, and treatments like surgery, radiation, or hormone therapy can be more effective. Without screening, many cases go undiagnosed until they ...